Precise staging of advanced HCC promotes higher quality of personalized treatment management: Chinese experts consensus on precision diagnosis and management of advanced hepatocellular carcinoma (2023)

References

[1] Zhou J,Wang Z.Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition).Liver Cancer2023;12:405-44

[2] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[3] National Clinical Research Center for Infectious Diseases; Society of Hepatology, Beijing Medical Association; Translational Medicine Branch, China Association of Gerontology and Geriatrics. Expert consensus on precise diagnosis and management of primary hepatocellular carcinoma in advanced stage (2023 version).Zhonghua Gan Zang Bing Za Zhi2023;31:910-20

[4] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition).Zhonghua Gan Zang Bing Za Zhi2022;30:367-88.

[5] Haber PK,Castet F.Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020).Gastroenterology2021;161:879-98

[6] Lencioni R,Torres F.Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.J Hepatol2017;66:1166-72

[7] Sonbol MB,Naqvi SAA.Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.JAMA Oncol2020;6:e204930 PMCID:PMC7582230

[8] McPherson S,Wendler MC.Methodology update: delphi studies.Nurs Res2018;67:404-10

[9] Piscaglia F,Cucchetti A.Treatment of hepatocellular carcinoma in Child-Pugh B patients.Dig Liver Dis2013;45:852-8

[10] Watanabe Y,Kato T.Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.Surg Endosc2023;37:1316-33 PMCID:PMC9540096

[11] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73

[12] Dual immunotherapy makes strides against HCC.Cancer Discov2022;12:OF1.

[13] Ren Z,Bai Y.ORIENT-32 study groupSintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol2021;22:977-90

[14] Yin J,Han Y.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.J Clin Oncol2013;31:3647-55.

[15] Huang G,Lau WY.Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial.Ann Surg2018;268:943-54

[16] Retraction: valproic acid protects neurons and promotes neuronal regeneration after brachial plexus avulsion.Neural Regen Res2022;17:250 PMCID:PMC8463989